welcome aboard guys, plan to follow this closely in the aftermarket and wouldn't be surprised to see this thread become fairly popular in due course.
Red I assume you will keep your market intelligence open to us!
I think that the main thing that will drive GBI in the short term is further demonstration of path lab players getting behind PapType (remember the Sonic deal is non-exclusive) and then development of new tests on the AmpaSand platform along with multiplexing.
The big blue sky will kick in with QSand developments.
Qsand as an ultra-sensitive biosensor can completely remove the need for PCR. PCR has so far earned approximately US$2 billion in royalties for the various rights-holders over the years and Roche charges approx an 18% royalty for its RT-PCR
also less headline grabbing but just as important will be ISO 13485 accreditation and GMP, then Sonic internal validation of PapType.
cheers
GBI Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Not Held
